United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

meda pharmaceuticals ltd - bromocriptine mesilate - oral tablet - 1mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - bromocriptine mesilate - oral capsule - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - bromocriptine mesilate - oral capsule - 10mg

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - bromocriptine mesilate, quantity: 2.87 mg (equivalent: bromocriptine, qty 2.5 mg) - tablet, uncoated - excipient ingredients: maleic acid; colloidal anhydrous silica; magnesium stearate; maize starch; lactose monohydrate; disodium edetate - prevention of onset of lactation in the puerperium for clearly defined medical reasons. therapy should be continued for 14 days to prevent rebound lactation. parlodel should not be used to suppress established lactation. treatment of hyperprolactinaemia where surgery and/or radiotherapy are not indicated or have already been used with incomplete resolution. precautions should be taken to ensure that the hyperprolactinaemia is not due to severe primary hypothyroidism. where the cause of hyperprolactinaemia is a prolactin-secreting microadenoma or macroadenoma, parlodel is indicated for conservative treatment; prior to surgery in order to reduce tumour size and to facilitate removal; after surgery if prolactin level is still elevated. adjunctive therapy in the management of acromegaly when: (1) the patient refuses surgery and/or radiotherapy; (2) surgery and/or radiotherapy has been unsuccessful or full effects are not expected for some months; (3) a manifestation of the acromegaly needs to be brought under con

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - bromocriptine mesilate, quantity: 11.5 mg (equivalent: bromocriptine, qty 10 mg) - capsule, hard - excipient ingredients: lactose monohydrate; gelatin; maize starch; colloidal anhydrous silica; magnesium stearate; maleic acid; titanium dioxide - prevention of onset of lactation in the puerperium for clearly defined medical reasons. therapy should be continued for 14 days to prevent rebound lactation. parlodel should not be used to suppress established lactation. treatment of hyperprolactinaemia where surgery and/or radiotherapy are not indicated or have already been used with incomplete resolution. precautions should be taken to ensure that the hyperprolactinaemia is not due to severe primary hypothyroidism. where the cause of hyperprolactinaemia is a prolactin-secreting microadenoma or macroadenoma, parlodel is indicated for conservative treatment; prior to surgery in order to reduce tumour size and to facilitate removal; after surgery if prolactin level is still elevated. adjunctive therapy in the management of acromegaly when: (1) the patient refuses surgery and/or radiotherapy; (2) surgery and/or radiotherapy has been unsuccessful or full effects are not expected for some months; (3) a manifestation of the acromegaly needs to be brought under con

Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - bromocriptine mesylate eqv bromocriptine - tablet - 2.5 mg

Canada - English - Health Canada

novartis pharmaceuticals canada inc - bromocriptine (bromocriptine mesylate) - tablet - 2.5mg - bromocriptine (bromocriptine mesylate) 2.5mg - ergot-derivative dopamine receptor agonists

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

sun pharma japan limited - bromocriptine mesilate - white tablet, diameter: 7.0 mm, thickness: 2.9 mm